• Mesenchymal Stem Cell Conditioned Media (MSC-CM) Augments the Inhibitory Impact of Sorafenib on Squamous Cell Carcinoma Cells
  • Amin Ebrahimi Sadrabadi,1,* Bahareh Hassani Derakhshandeh,2 Arsalan Jalili,3
    1. Cancer Biomedical Research Center, Tehran, Iran (CBC)
    2. Department of Biology, Central Tehran Branch, Islamic Azad University, Tehran, Iran
    3. Hematopoietic Stem Cell Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran


  • Introduction: Sorafenib is a kinase inhibitor drug approved for the treatment of renal cell carcinoma, hepatocellular carcinoma, and advanced thyroid carcinoma. Recently, Sorafenib is also widely used for some kind of lung cancer, especially Squamous Cell Carcinoma (NSCLC). The toxicity of Sorafenib is the primary concern in its therapeutic application. A new strategy to regulate the toxicity and increase the inhibitory effect of Sorafenib is the co-administration of Sorafenib with mesenchymal stem cell (MSC) secretions. MSC has been shown to inhibit NSCLC, so we hypothesized that low dose sorafenib co-administered with MSC-CM could act synergistically in the inhibition of NSCLC. In this study, the effect of Sorafenib was tested in combination with MSC_CM on the growth of the human NSCLC cell line.
  • Methods: Three human NSCLC cell lines, PC9, has been treated with Sorafenib and MSC_CM separately and in co-administration. Then, the viability and proliferation effect of these treatments on cancer cells was evaluated by WST-8 at 48 and 96 hours.
  • Results: Compared to the mechanism of either agent alone, the combination of low concentrations of sorafenib (<5 μM) and MSC-CM, demonstrated the enhanced inhibition of cell proliferation and growth.
  • Conclusion: This study shows that sorafenib co-administered with MSC-CM synergistically potentiates the sorafenib-mediated antitumor effect.
  • Keywords: NSCLC, Sorafenib, MSC_CM